MacroGenics Provides Vobramitamab Duocarmazine Update Abstract of clinical data accepted for poster presentation at ESMO Congress 2024 in SeptemberESMO poster to include protocol-defined TAMARACK Phase 2 mCRPC study data, including pre-defined landmark...

MacroGenics ALERT: Securities Fraud Lawsuit Could Allow Investors to Recover Losses; Block & Leviton Encourages Investors to Contact the Firm to Learn More Block & Leviton announces that a securities fraud lawsuit has been filed against MacroGenics, Inc. (NASDAQ: MGNX) and certain of its executives.

MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09,...

MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data,...